Equibles does not estimate personal net worth.
Get an email with a short summary when Arcturus Therapeutics Holdings Inc. publishes a filing, an earnings call transcript or a press release.
Get ARCT alertsPadmanabh Chivukula is recorded as COO at Arcturus Therapeutics Holdings Inc. (ARCT). The newest filing on record that lists Padmanabh Chivukula as COO at Arcturus Therapeutics Holdings Inc. (ARCT) is dated April 24, 2026. The proxy statement of Arcturus Therapeutics Holdings Inc. reports total compensation of $862,000 for Padmanabh Chivukula in fiscal 2025, including a base salary of $572,000. Disclosed compensation is on record for 8 fiscal years. Padmanabh Chivukula has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Arcturus Therapeutics Holdings Inc. on August 11, 2026. Arcturus Therapeutics Holdings Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcturus Therapeutics Holdings Inc. includes Joseph E. Payne (CEO and Board Member), Joseph Payne (CEO and Board Member), Andy Sassine (CFO and Board Member) and 7 others.
“You've just heard a metabolic physician say there's three things about ARCT810 that's safe, that it's tolerated, and it works. So the question is no No longer weather and mRNA medicines can treat OTC deficiency.”
“Well, first of all, we worked for many years with the CF Foundation to develop our preclinical package. And we've done quite a bit of work on looking at LNP stability in sputum.”
“In our initial preclinical work, we focused heavily on how mucus and clogging affect the delivery of our nanoparticles and the expression of mRNA. We optimized our formulations to ensure they are stable in sputum, allowing them to diffuse and reach the appropriate cell type.”
“No. I think you've identified the key point, Joe. Our therapeutic approach using mRNA does not depend on mutations, allowing us to target a wider group of patients.”
“We anticipate dosing all the cohorts altogether. That's correct.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
COO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $572,000 | $862,000 |
| 2024 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $550,000 | $1,585,000 |
| 2023 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $550,000 | $3,178,500 |
| 2022 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $525,000 | $3,106,000 |
| 2021 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $500,000 | $750,000 |
| 2020 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $400,000 | $7,472,600 |
| 2019 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $370,000 | $636,156 |
| 2018 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Scientific Officer, Chief Operating Officer | $350,000 | $1,372,905 |
